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B R I E F R E P O R T
Role of Hepatitis B Virus Genotypes
in Chronic Hepatitis B Exacerbation
Man-Fung Yuen,1 Erwin Sablon,2 Danny Ka-Ho Wong,1 He-Jun Yuan,1
Benjamin Chun-Yu Wong,1 Annie On-On Chan,1 and Ching-Lung Lai1
1Department of Medicine, The University of Hong Kong, Queen Mary Hospital,
Hong Kong, and 2Innogenetics, Ghent, Belgium
Hepatitis B virus (HBV) genotypes and precore and core
promoter mutations were determined in 318 patients with
HBV. Patients infected with HBV genotype B had a higher
median alanine aminotransferase level and bilirubin level
and a lower median albumin level during exacerbations of
disease, compared with patients infected with HBV genotype
C (all ). By logistic regression analysis, HBV genotypeP ! .001
B infection ( ) and low albumin levels ( )Pp .014 Pp .006
were independently associated with a higher risk of hepatic
decompensation during severe exacerbations of disease. Pa-
tients infected with genotype B had a significantly higher
mortality due to hepatic decompensation than did patients
with genotype C (70% vs. 27.8%; ).Pp .05
There is growing evidence that hepatitis B virus (HBV) ge-
notypes may play some role in causing different disease profiles
in chronic hepatitis B (CHB). Among Asians, who constitute
75% of the worldwide population of individuals with CHB
[1], genotypes B and C are the 2 most common HBV genotypes
[2]. Though genotype B can be subdivided into genotype Bj,
representing genotype B found among infected individuals
from Japan, and genotype Ba, representing genotype B found
among individuals from the rest of Asia [3], most infected non-
Japanese Asians have genotype Ba only. In this article, references
to genotype B refer to genotype Ba unless otherwise noted.
A study from Taiwan shows that young patients with he-
patocellular carcinoma are more likely to be infected with
HBV genotype B than genotype C, whereas patients with
more-advanced liver disease are more likely to be infected
with genotype C than genotype B [4]. Other studies dem-
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onstrate that, compared with patients with genotype C in-
fection, patients with genotype B infection have more serious
liver disease [5–7]. Recent studies show that patients with
genotype B achieve hepatitis B e antigen (HBeAg) serocon-
version a decade earlier than do patients with genotype C [8,
9]. Regarding responsiveness to treatment, there is some ev-
idence that patients with genotype B respond better to IFN-
a when compared with patients with genotype C [10, 11].
However, the effect of HBV genotypes on HBV disease ex-
acerbations has not been studied. We aimed to investigate, in
a cross-sectional study, the relationship of HBV genotypes to
the probability and severity of HBV disease exacerbations
among Chinese patients with CHB.
Patients and methods. During the period 2000–2001, 73
patients (group I) who were admitted to Queen Mary Hospital,
The University of Hong Kong, Hong Kong, with severe exac-
erbations of hepatitis B disease and symptoms of hepatitis were
recruited for our study. All 73 patients had tested positive for
hepatitis B surface antigen for 16 months. “Severe exacerba-
tion” of disease was defined as an increase of alanine amino-
transferase (ALT) levels to 110 times the upper limit of normal
(ULN). Patients with evidence of other hepatotrophic virus
infection, checked by testing with antibodies to hepatitis A, C,
D, and E, were excluded. Patients with a history and clinical
features of drug-induced hepatitis, alcoholic hepatitis, and stea-
tohepatitis were also excluded. Of the 73 patients with severe
exacerbations of disease, 30 patients had hepatic decompen-
sation, defined as an elevated bilirubin level 12 times ULN and
prolonged prothrombin time (PT) of 5 s greater than the con-
trol value with or without development of ascites or hepatic
encephalopathy. The liver biochemistry, PT, and HBV DNA
levels (determined by Digene Hybrid Capture II assay [Digene;
lower limit of detection, 140,000 copies/mL]) were measured
at presentation. Patients were monitored for development of
ascites and hepatic encephalopathy, and liver functions and PT
were measured throughout the study period.
Patients first seen at the Hepatitis Clinic, Queen Mary Hos-
pital, The University of Hong Kong, Hong Kong, during the
same period of recruitment as the patients in the severe ex-
acerbation group (group I) were recruited as control subjects.
They were categorized into 3 different groups, as follows: 44
patients (group II) with moderate exacerbation of disease (de-
fined as ALT levels 5–10 ULN), 80 patients (group III) with
mild exacerbation of disease (ALT levels 2–5 ULN), and 121
patients (group IV) with no exacerbation of disease (ALT levels
!2 ULN).
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Table 1. Demographic and clinical data of 4 groups of patients with hepatitis B virus (HBV) infection.
Variable
Disease exacerbation group
Severe
(group I)
Moderate
(group II)
Mild
(group III)
None
(group IV)
No. of patients 73 44 80 121
Sex, no. male/no. female 55/18 24/20 63/17 85/36
Age in years, median (range) 37.2 (17.8–67.9) 36.3 (18.5–65.2) 38.0 (21.2–68.3) 38.1 (22.7–80.5)
HBeAg/anti-HBe, n/na 43/30 26/18 36/44 71/50
Laboratory values, median (range)
ALT, U/L 719 (400–3840) 278 (162–498) 136 (75–249) 41 (7–104)
Albumin, g/L 38 (19 –51) 42 (31–53) 45 (29–55) 44 (32–53)
Bilirubin, mmol/L 56.5 (6–810) 13.5 (5–298) 12 (3–38.7) 11 (4–36)
HBV DNA, 106 copies/mL 0.93 (!0.14–1261.5) 3.8 (!0.14–986.1) 2.6 (!0.14–1380.2) 1.2 (!0.14–313.1)
US evidence of cirrhosis, n/N (%)b
All genotypes 12/50 (24) 4/22 (18.2) 10/43 (23.3) 8/35 (22.9)
Genotype B 5/24 (20.8) 2/6 (33.3) 3/13 (23.1) 2/11 (18.2)
Genotype C 6/23 (26.1) 2/16 (12.5) 6/28 (21.4) 5/22 (22.7)
NOTE. “Severe exacerbation” was defined as an increase of alanine aminotransferase (ALT) levels to 110 times the upper limit of normal (ULN).
“Moderate exacerbation” was defined as an increase of ALT levels to 5–10 ULN. “Mild exacerbation” was defined as an increase of ALT levels to
2–5 ULN. “No exacerbation” was defined as an increase of ALT levels to !2 ULN. The median ALT levels increased significantly from group I to
group IV (all ). Group I had a significantly lower median albumin level and higher bilirubin level compared with those of other groups (allP ! .001 P !
). US, ultrasonographic..001
a No. of patients testing positive for hepatitis B e antigen/no. of patients testing positive for antibody to hepatitis B e antigen.
b No. of patients with evidence of cirrhosis/no. for whom ultrasonography was performed (%).
Table 2. Distribution of hepatitis B virus (HBV) genotypes and
mutations in and among 4 groups of patients with HBV infection.
Infecting genotype,
mutation location
and class
No. (%) of patients,
by disease exacerbation group
Severe
(n p 67)
Moderate
(n p 41)
Mild
(n p 67)
None
(n p 110)
Genotype B 31 (46.3) 13 (31.7) 19 (28.4) 39 (35.5)
Precore region
Wild-type 4 (12.9) 3 (23.1) 1 (5.3) 10 (25.4)
Mutant 27 (87.1) 10 (76.9) 18 (94.7) 29 (74.6)
Core promoter
Wild-type 18 (58.1) 9 (69.2) 11 (57.9) 29 (74.6)
Mutant 13 (41.9) 4 (30.8) 8 (42.1) 10 (25.4)
Genotype C 36 (53.7) 28 (68.3) 48 (71.6) 71 (64.5)
Precore region
Wild-type 23 (63.9) 19 (67.9) 37 (77.1) 50 (70.4)
Mutant 13 (36.1) 9 (32.1) 11 (22.9) 21 (29.6)
Core promoter
Wild-type 6 (16.7) 2 (7.1) 2 (4.2) 8 (11.3)
Mutant 30 (83.3) 26 (92.9) 46 (95.8) 63 (88.7)
The genotypes as well as the precore and core promoter
mutations of the infecting HBV strains in all patients were
determined with a line probe assay (INNO-LiPA HBV Geno-
typing and INNO-LiPA HBV Precore, developed by Innoge-
netics). The methodologies of these assays have been described
in our previous studies [9, 12].
All statistical analyses were performed using the SPSS version
10.0 for Windows (SPSS). Continuous variables with skewed
distribution were tested by Mann-Whitney U test. Categorical
variables were tested by x2 test or Fisher’s exact test. Logistic
regression was applied to test independent association of var-
ious variables with outcome.
Results. The demographic and clinical data for the patient
groups are listed in table 1. There were no differences in the
median age, sex ratio, proportion of HBeAg to antibody to
HBeAg positivity, proportion of patients with ultrasonographic
evidence of cirrhosis, and median HBV DNA level between the
4 groups of patients. Group I patients (i.e., with severe exac-
erbations) had a significantly higher median ALT level, lower
median albumin level, and higher median bilirubin level com-
pared with the other 3 groups (all ).P ! .001
The number and percentages of patients with single genotype
B or C infection and the prevalences of HBV precore and core
promoter mutations in different groups are listed in table 2. There
were no significant differences in the prevalence of genotype B
and genotype C between the 4 groups (all ). In total,PpNS
there were 102 patients with single genotype B infection and 183
patients with single genotype C infection. Infection with genotype
B was associated with a higher prevalence of precore mutations
(84 [82.4%] of 102 patients), compared with infection with ge-
notype C (54 [29.5%] of 183; OR 11.1; 95% CI, 6.1–20.3; P !
). In contrast, infection with genotype C was associated with.001
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Table 3. Differences in demographic and clinical data between patients
infected with hepatitis B virus (HBV) genotype B and those infected with
genotype C.
Variable
Patients infected with HBV
P
Genotype B
(n p 63)
Genotype C
(n p 112)
Median age (range),
years
37.6 (17.8–68.28) 37.0 (18.5–67.93) .19
Sex, no. male/no.
female
53/10 75/37 .014
HBeAg/anti-HBe, n/na 31/32 66/46 .21
Laboratory values,
median (range)
ALT, U/L 304 (71–3840) 229 (69–2420) .047
Albumin, g/L 41 (19–51) 43 (24–55) .02
Bilirubin, mmol/L 23 (5–801) 13 (3–810) !.001
HBV DNA, copies
 106/mL
1.6 (!0.14–1261.5) 3.7 (!0.14–1380.2) .61
NOTE. ALT, alanine aminotransferase.
a No. of patients testing positive for hepatitis B e antigen/no. of patients testing positive
for antibody to hepatitis B e antigen.
a higher prevalence of core promoter mutations (165 [90.2%]
of 183 patients), compared with infection with genotype B (35
[34.3%] of 102; OR 17.5; 95% CI, 9.3–33.1; ).P ! .001
All patients with exacerbations of disease (groups I, II, and
III) were categorized according to whether they were infected
with HBV genotypes B or C. The clinical and the liver bio-
chemistry data obtained during periods of exacerbation are
listed in table 3. Patients infected with genotype B had a higher
median ALT level, higher median bilirubin level, and lower
median albumin level during periods of exacerbation, com-
pared with patients infected with genotype C. This means that
patients infected with genotype B had more severe exacerba-
tions compared with those had by patients infected with ge-
notype C.
The prevalence of genotype B among and the liver biochem-
istry data for the 73 patients who had severe exacerbations with
and without hepatic decompensation are reported in table 4.
By logistic regression analysis, infection with genotype B and
low albumin levels were independently associated with a higher
risk of hepatic decompensation in patients with severe exac-
erbations ( and , respectively), though it isPp .014 Pp .006
difficult to distinguish whether the low albumin levels were of
causal significance or were only the outcome of the hepatic
decompensation.
Of the 30 patients with hepatic decompensation, 13 were
given lamivudine (1–20 days before admission, for 8 patients;
on admission, for 4; and on day 19 after admission, for 1).
Single infection with genotype B was found in 10 patients and
single infection with genotype C was found in 18 patients. The
remaining 2 patients had coinfection with genotypes A and C
and genotypes A and B. Patients infected with genotype B had
a higher mortality due to hepatic decompensation caused by
severe exacerbations (7 [70%] of 10), compared with patients
infected with genotype C (5 [27.8%] of 18; OR 6.1; 95% CI,
1.1–33.4; ).Pp .05
Discussion. Because nearly all patients we studied with
HBV infection in the Chinese population became infected dur-
ing the perinatal period or within the first 1–2 years of life, it
is unlikely that there is any difference in the duration of in-
fection for patients infected with genotypes B and C. In the
present study, there was no difference in the probability or the
severity of exacerbations of disease, graded according to the
ALT levels at presentation, for patients infected with genotypes
B and C; this was because the prevalence of genotypes B and
C was similar in all 4 groups. Though group I patients had a
higher prevalence of genotype B (46.3%), compared with the
other 3 groups (range, 28.4–35.5%) (table 2), the difference
was not statistically significant. However, when all the patients
with exacerbations were grouped together (table 3), patients
infected with genotype B had more severe exacerbations, com-
pared with patients infected with genotype C, as reflected by
the higher ALT, higher bilirubin, and lower albumin levels
( , , and , respectively).Pp .047 P ! .001 Pp .02
We also found that, when the exacerbations were severe, pa-
tients infected with genotype B had a higher risk of hepatic
decompensation, compared with patients infected with genotype
C. Furthermore, among patients who had hepatic decompen-
sation caused by severe exacerbations, patients infected with ge-
notype B had a higher mortality rate than did patients infected
with genotype C . The higher rates of hepatic decompensation
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Table 4. Prevalence of genotype B among and liver biochemistry data for 73 pa-
tients with severe exacerbations of hepatitis B virus (HBV) infection with and without
hepatic decompensation.
Variable
Patients
with hepatic
decompensation
(n p 30)
Patients
without hepatic
decompensation
(n p 43) P
HBV genotype B, n/N (%)a 20/28 (71.4) 11/39 (28.2) .0001b
Median albumin level (range), g/L 32.5 (19–49) 44 (29–51) !.001
Median bilirubin level (range), mmol/L 224.5 (17–740) 16 (6–583) !.001
NOTE. “Severe exacerbation” was defined as an increase of alanine aminotransferase (ALT)
levels to 110 times the upper limit of normal.
a No. of patients with HBV genotype B infection/no. for whom HBV genotype information was
known (%).
b OR, 6.4; 95% CI (2.2–18.7).
and mortality among patients infected with genotype B compared
with patients infected with genotype C suggests that HBV ge-
notype B may be more immunogenic and hence cause more
severe immune-system–mediated damage. Studies have shown
that patients infected with genotype B have earlier HBeAg se-
roconversion, compared with patients with genotype C [8, 9].
These studies suggest that the immune-system–mediated attack
during the immunoclearance phase may be more pronounced
and, hence, associated with a higher rate of HBeAg seroconver-
sion in patients infected with genotype B. Immunological studies
examining the cytotoxic T lymphocyte responses against the
hepatitis B core antigen and HBeAg in patients infected with
genotypes B and C are necessary to prove this hypothesis. With
reference to clinical symptoms, a longitudinal study measuring
the ALT and HBV DNA levels and monitoring the duration of
exacerbations is also required.
Infection with genotype B was associated with precore mu-
tations and infection with genotype C was associated with core
promoter mutations. This finding is similar to the findings of
our previous report, as well as the findings of studies by other
groups [9, 13]. It would be interesting to examine whether the
association between genotype B infection and precore muta-
tions contributes to the adverse outcome for patients with se-
vere exacerbations of disease. Unfortunately, among the 31 pa-
tients in the present study infected with genotype B infection
who had severe exacerbations, only 4 patients (12.9%) had HBV
with a wild-type precore region (table 2).
In conclusion, the present study suggests that patients with
HBV genotype B infection had more severe exacerbations of
disease and a higher risk of hepatic decompensation and mor-
tality due to severe exacerbations, compared with patients with
HBV genotype C infections. Previous longitudinal studies of
acute exacerbations in patients with chronic HBV infection
have demonstrated convincingly that acute exacerbations are
usually not associated with infection with viral genotypes other
than the original genotype [14, 15]. Further longitudinal studies
should be designed to follow up a large population of patients
with CHB and define the impact of the difference in exacer-
bations of disease among patients infected with genotypes B
and C on the progression of the disease and the development
of complications.
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E R R A T U M
An error appeared in a Brief Report published in the 15
August 2003 issue of the journal (Yuen MF, Sablon E, Wong
DKH, Yuan HJ, Wong BCY, Chan AOO, Lai CL. Role of hep-
atitis B virus genotypes in chronic hepatitis B exacerbation.
Clin Infect Dis 2003; 37:593–7). In the last paragraph of Results,
after the first sentence, it should read, “Single infection with
genotype B was found in 18 patients, and single infection with
genotype C was found in 10 patients. The remaining 2 patients
had coinfection with genotypes A and C and genotypes A and
B. There was no significant difference in the mortality rate due
to hepatic decompensation caused by severe exacerbation be-
tween patients with genotype B and C (7 [38.9%] of 18 vs. 5
[50%] of 10, respectively; )” (not “Single infection withPp .87
genotype B was found in 10 patients and single infection with
genotype C was found in 18 patients. The remaining 2 patients
had coinfection with genotypes A and C and genotypes A and
B. Patients infected with genotype B had a higher mortality
due to hepatic decompensation caused by severe exacerbations
(7 [70%] of 10), compared with patients infected with genotype
C (5 [27.8%] of 18; OR 6.1; 95% CI, 1.1–33.4; ”). ThePp .05
authors regret this error.
